Cadaveric Human Growth Hormone-Associated Creutzfeldt-Jakob Disease with Long Latency Period, United States

PubMed

Insights

A patient developed iatrogenic Creutzfeldt-Jakob disease (iCJD) after a 48.3-year incubation period following cadaveric human growth hormone treatment. This case highlights the long incubation period of iCJD and the need for clinical vigilance.

Area of Science:

  • Neurology
  • Pathology
  • Infectious Diseases

Background:

  • Creutzfeldt-Jakob disease (CJD) is a rare, fatal neurodegenerative prion disease.
  • Iatrogenic CJD (iCJD) can occur through medical procedures or contaminated treatments.
  • Cadaveric human growth hormone (hGH) therapy was a historical route for prion transmission.

Observation:

  • A patient presented with progressive neurological decline.
  • The patient had a history of treatment with cadaveric hGH.
  • A 48.3-year incubation period was estimated between treatment and symptom onset.

Findings:

  • Pathological examination confirmed iatrogenic Creutzfeldt-Jakob disease.
  • Genetic analysis ruled out familial CJD mutations.
  • The extremely long incubation period is a key finding.

Implications:

  • Clinicians must consider iCJD in patients with unexplained progressive neurological symptoms, especially those with a history of cadaveric hGH treatment.
  • This case underscores the risk of prion disease transmission via contaminated biological products.
  • Awareness of long incubation periods is crucial for diagnosing rare neurodegenerative diseases.